Search

everythinglearnresearchcommunity

for

Search:↓

Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Tofacitinib is an effective and safe treatment for alopecia areata.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Oral Apremilast effectively treats alopecia areata in most patients.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Zinc levels are not significantly linked to the presence or severity of alopecia areata.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Tofacitinib effectively treats Alopecia Areata.

The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

People with alopecia areata often have low vitamin D levels, which may worsen their hair loss.

Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.

Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.